Phase 2 Breast Cancer Trial, Recruiting NCT07389733 Sponsor: Shandong Suncadia Medicine Co., Ltd. Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07389733
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman between 18 and 75 years old (inclusive)
  • You have a good general level of physical functioning, meaning you are fully active or able to carry out light work (confirm with trial site)
  • Your doctors expect you to live for at least 12 weeks or more
  • Your blood counts and organ function (such as liver and kidneys) are at acceptable levels (confirm with trial site)
  • If you are able to become pregnant, you must agree to use effective birth control from the time you sign the consent form, throughout the study, and for up to 2 years after your last dose of the study medicine
  • You are willing to give written consent to take part in the trial before it begins

Who may not be able to join:

  • You have had another type of cancer in the past 5 years, with some exceptions such as certain fully treated skin cancers or thyroid cancer (confirm with trial site)
  • You have active cancer that has spread to the brain, the lining of the brain, or the spinal cord, or you have had a primary brain tumour
  • You have severe bone damage caused by cancer that has spread to your bones, as judged by the study doctor
  • You still have unresolved side effects from a previous cancer treatment
  • You have difficulty swallowing or absorbing tablets or oral medicines (confirm with trial site)
  • You have a history of serious heart or stroke-related conditions
  • You currently have a serious active infection
  • You have had a significant bleeding episode within the 3 months before starting the study
  • You have an active autoimmune disease, a weakened immune system, HIV infection, a condition requiring long-term steroids or immune-suppressing medicines, or have had an organ transplant
  • You have active hepatitis that is currently untreated
  • You have had active tuberculosis (TB) within the past year, or had TB more than a year ago that was not properly treated
  • You have not waited long enough after stopping previous treatments before joining this trial (confirm with trial site)
  • You are currently taking certain medicines that are not allowed in this trial (confirm with trial site)
  • You are pregnant, breastfeeding, or planning to become pregnant within 2 years of your last dose of study medicine
  • You have a significant history of neurological or psychiatric conditions, or a history of substance or drug addiction
  • You have had an allergic reaction to any ingredient in the study medicine
  • The study doctor has another reason they feel makes it unsuitable for you to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
27 March 2026
Est. completion
1 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity (DLT); Recommended phase II dose (RP2D); Incidence and severity of adverse events (AEs); Objective response rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov